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know. There are known unknowns. That is to say, there are
things that we know we don't know. But there are also unknown
unknowns. There are things we don't know we don't know.
Donald Rumsfeld
Clopidogrel is a pro-drug which requires conversion by
several hepatic cytochromeP450 (CYP) isoenzymes to its active
metabolite, which then irreversibly binds to platelet P2Y12 re-
ceptors and inhibits platelet activation. There is considerable
variability in the response to clopidogrel in clinical practice.1
Some genetic polymorphisms in the CYP enzymes, particu-
larly CYP2C19, have consistently been shown to be associated
with higher residual platelet reactivity and ischemic cardio-
vascular events while on treatment with clopidogrel.2 As pra-
sugrel and ticagrelol are not metabolized by these enzymes,
these polymorphisms have little effect on platelet reactivity
and ischemic events with these agents.3,4 Given that the loss-
of-function CYP2C19*2 allele (the variant most reproducibly
associated with a reduced response to clopidogrel) is highly
prevalent in the general population,1,5 it is reasonable to ask
why genomic testing should not be used routinely to guide the
choice of antiplatelet therapy, as Rath and colleagues report in
this issue of the Journal.
The answer to this question is not as simple as it appears at
first glance. There are several issues to consider when evalu-
ating the utility of a diagnostic test. First and foremost is the
ability of the test to discriminate reliably between people who
have the condition of interest and those who don't. Second,
the detected condition should be reasonably common so as to
make testing for it worthwhile. Third, a “positive” test should
consistently be associated with the relevant clinical outcome.
Finally, knowledge of the test result should help in improving
clinical outcomes through appropriate treatment. Genotyping
for the isoenzymes involved in clopidogrel metabolism easilyE-mail address: karthik2010@gmail.com.
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are highly accurate, and they reliably and reproducibly iden-
tify variants of interest. Some of the loss-of-function alleles
may be present in as many as half those tested, particularly in
some ethnic groups. However, although these variants are
clearly related to reduced platelet responsiveness to clopi-
dogrel, their relationship to clinical outcomes is less certain.
In a meta-analysis exploring this issue, Holmes and col-
leagues found that the presence of reduced function CYP2C19
alleles did not affect the rate of ischemic clinical events when
only the adequately powered studies were considered (i.e., in
those reporting 200 clinical events; RR 0.97, 95% CI
0.86e1.09).6 The “irrational exuberance” for clopidogrel phar-
macogenomic testing was plausibly driven by publication bias
and the related “small-study” effect.7 More importantly, there
is no evidence to date that intervention based on knowledge of
CYP2C19 status affects outcomes, as none of the studies were
large enough to detect differences in clinical events. On the
contrary, indirect evidence derived from studies involving
targeted treatment of patients with reduced platelet respon-
siveness (due to any cause), suggests that clinical outcomes
may not be affected. Two randomized studies targeting
reduced responsiveness to clopidogrel (identified by func-
tional testing and not based on CYP2C19 status) using higher
clopidogrel doses,8 or prasugrel and glycoprotein IIb-IIIa an-
tagonists,9 did not show improvement in clinical outcomes.
The study by Rath et al does not provide any information
either on the functional or clinical outcomeswith switching to
a different antiplatelet agent.known and unknown unknowns
The lack of effect of reduced function CYP2C19 alleles on
clinical outcomes may seem intriguing, but it is important toreserved.
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platelet reactivity and its links to clinical outcomes is far from
complete. For example, it is known that clinical and de-
mographic factors such as age, diabetes, body-mass index,
leftventricular function, drugedrug interactions and systemic
inflammation, may all independently influence on-treatment
platelet reactivity through multiple mechanisms.10 It should
also be kept in mind that numerous other polymorphisms
affecting other isoenzymes (including those that augment
clopidogrel metabolism and action) may affect platelet
responsiveness.11 Consequently, it is estimated that only
about 12% of the variation in platelet responsiveness is
explained by CYP2C19 polymorphisms.12 In assessing the
value of routine genotyping for patients on clopidogrel in the
Indian context, we must also consider the resultant increase
in cost of therapy (both from the cost of testing and the cost of
adding prasugrel or ticagrelol), its potential adverse impact on
compliance and clinical outcomes. The idea of individualized
medicine holds immense appeal for doctors, patients and the
general public, and optimistically, will become feasible for
many conditions in the future. But routine genotyping for
patients on clopidogrel cannot be advocated until convincing
data on a favorable impact on clinical outcomes becomes
available.r e f e r e n c e s
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